Lipoprotein(a) Is Associated With Increased Risk of Abdominal Aortic Aneurysm

JACC Basic to Translational Science 2026 Open access

Read full text
Authors: Pranav Sharma, Renae Judy, Shuai Yuan, Corry Gellatly, Katie Saxby, Daniel J. Rader, Matthew J. Bown, Michael G. Levin, Scott M. Damrauer
DOI: 10.1016/j.jacbts.2025.101457
Cited by: 2
References: 45

Abstract

Lp(a) is a genetically determined lipoprotein targeted by emerging therapies. In a UK Biobank analysis (1,026 abdominal aortic aneurysm [AAA] cases, 469,989 controls), elevated Lp(a) was associated with increased risk of AAA, including at clinically relevant thresholds while controlling for traditional risk factors, including ApoB. Multivariable Mendelian randomization confirmed a causal relationship between lipoprotein(a) [Lp(a)] and AAA independent of apolipoprotein B. These findings support Lp(a) as a modifiable risk factor and potential therapeutic target for AAA, a condition with limited medical treatment options. AAA should be considered as an outcome in future clinical trials of Lp(a)-lowering therapies.

Fields of Study & Subjects

Lipoproteins and Cardiovascular Health Aortic aneurysm repair treatments Peripheral Artery Disease Management

Publication details

Journal / source
JACC Basic to Translational Science
Publisher
Elsevier BV
Volume
11
Issue
2
Pages
101457–101457
Publication date
6 January 2026
Language
EN